PMV Pharmaceuticals, Inc., a precision oncology company, is dedicated to the discovery and development of small molecule tumor agnostic therapies for p53 mutations in cancer. The company is headquartered in Cranbury, New Jersey.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-83.53M |
| Operating Margin | 0.00% |
| Return on Equity | -63.20% |
| Return on Assets | -39.10% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.96 |
| Price-to-Book | 0.94 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.24 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $53.46M |
| Float | $46.20M |
| % Insiders | 3.35% |
| % Institutions | 64.72% |
Volatility is currently contracting
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PMVP and any ticker you trade — then tracks every position and per-strategy win rate.
